FDA approval of ketamine spray signals ‘major shift’ in depression therapy
It is ‘quite likely’ the TGA will approve the drug to treat resistant depression in Australia, says psychiatrist
![Ketamine formula](https://www.ausdoc.com.au/wp-content/uploads/2022/08/ketamine-istock-506904156-1.jpg)
The approval by the US Food and Drug Administration of a ketamine-like nasal spray for treatment-resistant depression has been described as a paradigm shift by a leading Australian psychiatrist.
Last week the US regulator gave the green light to Spravato, which contains the ketamine derivative esketamine, following several short trials that included Australian patients.